There is clear evidence that this drug can cure COVID 19 patients

The US has relied on the drug Remedisvir for the treatment of Kovid 19 disease, saying that there is clear evidence that this drug can cure COVID 19 patients. A clinical trial of this drug has revealed that the symptoms start appearing in patients within 11 days instead of 15 days. However, so far no information has been revealed about the investigation conducted on this drug.

Experts say that if the claims related to this drug are confirmed then there will be great news of the current era. But he has also said that this medicine is not like the magic bud for this disease. This drug will develop the ability to save lives, reduce the burden on hospitals, and remove lockdowns in some places.

Where did this medicine come from?

This drug was originally developed to treat Ebola. It is an antiviral drug. When a virus enters the human body, it replicates itself to make its own copies. And this happens in the cells of the human body. But in this process, the virus needs an enzyme. By attacking this enzyme, this drug forms a barrier in the path of the virus.

In the US, this drug has been tried at the National Institute of Allergy and Infectious Diseases of America. 1063 people participated in this trial. Some of these patients were given this drug. At the same time, some patients were given Pelecibo. In the world of medicine, placebo means something that does not have any medical properties. These may include things like water and sugar tablets.

How successful is this medicine?

Head of the National Institute of Allergy and Infectious Diseases of America, Dr. Anthony Fauchi has said that the trial data shows that this drug is proving effective in curing patients suffering from Kovid 19. He has said that the drug can block the virus and was told that we will now have the way that we can treat patients.

However, this drug has no apparent effect on deaths from Kovid 19. Those who were given this drug had an 8 percent mortality rate. At the same time, those who were given a placebo had 11.6 percent. But these results are not important from a statistical basis. This means that scientists are not able to tell whether the difference in mortality is accurate or not.

It is not clear who is benefiting.

Is it helping those who recover more quickly, who would have been cured even without medication?

In which age group does the medicine more or less work better?

Is this disease protecting people from going to ICU?

Does this medicine work better with the young and old?

Or which of these drugs affects sick or healthy people?

Do patients need to be cared for at the initial stage only when the virus is at its peak?

When detailed information related to this drug will be released, then answers to such specific questions will be revealed. Because this drug can have benefits such as the removal of lockdown along with saving people's lives.